Literature DB >> 3160383

Cyclical neutropenia and T8 lymphocyte mediated stimulation of granulopoiesis.

J G Smith, A K Seenan, M A Smith, E Galloway, M J Lesko, N P Lucie, M R Robertson, R M Rowan.   

Abstract

A 33-year-old female with cyclical neutropenia and a reciprocally cycling T8 (suppressor/cytotoxic) lymphocytosis was investigated. T8 lymphocytes ranged between 1.4 and 5.6 X 10(9)/l and a significant proportion (50-75%) were preactivated (1a+). Fc gamma receptors were detected in only a minority (7-10%). Functional studies on the lymphocytes indicated that despite their phenotype, little natural killer and reduced suppressor activities were present. Anti-granulocyte antibodies were not detectable in the serum. Production of colony stimulating activity (CSA) was assessed in the patient and control subjects' lymphocytes. Using a methylcellulose marrow culture system, the CSA production by the patient's lymphocytes was markedly increased compared with the control. Monoclonal antibody cytotoxic experiments confirmed that the T8 lymphocytes were responsible. As peaks of circulating T8 lymphocytes were synchronous with granulopoietic activity in the marrow, the above findings may represent a homeostatic mechanism which is attempting to compensate for an underlying stem cell defect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160383     DOI: 10.1111/j.1365-2141.1985.tb07445.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages.

Authors:  M A Smith; S M Knight; P J Maddison; J G Smith
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Adult-onset cyclic neutropenia is a benign neoplasm associated with clonal proliferation of large granular lymphocytes.

Authors:  T P Loughran; W P Hammond
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.